In a recent study, published in 2021 by MarjutNiinivirta et al., was reported that high expression of ELTD1 in the tumor vasculature predicts a favorable response to sunitinib treatment, in patients with metastatic renal cell cancer [22]. The gene discussed is ADGRL4; the disease is neoplasm.